Dr. Gonzalez-Martin on the Impact of the PRIMA Trial in Advanced Ovarian Cancer

Antonio Gonzalez-Martin, MD, co-director, Department of Medical Oncology, Clinica Universidad de Navarra, discusses the impact of the phase III PRIMA trial findings on clinical practice in advanced ovarian cancer.

The data from the PRIMA trial taken collectively with the data from phase III PAOLA-1 and VELIA trials are going to change the landscape of ovarian cancer, says Gonzalez-Martin. In PRIMA, niraparib (Zejula) maintenance led to a 38% reduction in the risk of progression or death versus placebo in patients with newly diagnosed, platinum-sensitive advanced ovarian cancer, regardless of biomarker status.

Notably, the PRIMA trial included patients for whom current treatment strategies are not as beneficial, adds Gonzalez-Martin, such as those who received neoadjuvant chemotherapy and bevacizumab (Avastin). These data represent a new standard of care in the overall population of patients with platinum-sensitive ovarian cancer, particularly those mentioned above who derived a significant benefit from niraparib maintenance, concludes Gonzalez-Martin.